Static list review decision – August 2017
Decision to transfer the guidance to the static guidance list
Further to our letter of 5 April 2017, we would like to update you on the decision made regarding the review of the existing guidance on TA292; Aripiprazole for the treatment of acute manic and mixed episodes in children with bipolar disorder.
The Institute was proposing that the guidance should be transferred to the static guidance list.
After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
Consequently, the guidance will now be transferred to the static guidance list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.
This page was last updated: